A shadow market for unapproved slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Investigational Treatment Gaining Traction Via Social Media
Retatrutide, which is still in research studies, is being promoted by social media influencers for its alleged fat-burning properties. Followers are urged to contact these profiles directly for supplier links, while also receiving promotional offers.
Active Commerce on Messaging Platforms
Additionally, a flourishing market exists on Telegram, where communities with thousands of members share comparison photos, injection guides and assertions of next-day UK delivery. Vendors market the substance there before redirecting buyers to WhatsApp for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injection developed by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could assist individuals reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.
Medical Professionals Voice Concerns
Nevertheless, physicians and chemists have warned that the distribution of what is still an unapproved medication in the UK is a cause for concern and could result in individuals injecting products of unknown origin.
Several experts stated the demand for retatrutide could be linked to the increasing cost of licensed weight loss products such as Mounjaro.
Legal Position and Enforcement
Marketing retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that must not be marketed or distributed for personal consumption under the British medical regulations.
Some influencers try to circumvent the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach medicines, marketing, and consumer regulations, potentially leading to penalties, legal action or prison.
Platform Response and Material Removal
According to the social media company, the service has taken down violative content and prohibited associated hashtags and query recommendations. The company stated it was committed to maintaining the service secure and allocating resources in enhancing enforcement strategies.
Digital Trading Activities
Investigations also discovered communities with up to 9,000 participants marketing the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays groups with thousands of members, populated with photos of slimming results, positive reviews and detailed instructions for preparing or injecting at home.
Within minutes of joining one group, a seller posted WhatsApp details, where the majority of purchases occur. The vendor provided an guidebook and promised shipping within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a image of a alleged testing documentation. Not one inquired about body mass, health issues or past usage.
Item Information and Costs
Within these communities, messages display black plastic parcels with postal service stickers, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, prepared at home with sterile water, or pre-filled injectors typically sold at £160 for 20 milligrams. When questioned how long a injector should be used, sellers give conflicting responses ranging from a several days to “depends on your body”.
Service Moderation and Security Measures
A spokesperson for Telegram said it actively moderated harmful material on its service including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are injecting substances they can’t verify. Even if the science behind this drug is valid, these online versions may not contain what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent cost increases for approved slimming medications such as Mounjaro. “With prices rising, individuals are using social media. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the environment they were produced in was sterile,” she explained.
Her staff has previously encountered patients harmed by personal administration from unverified suppliers. “We understand the frustration, but buying from messaging apps or WhatsApp is taking chances with your health,” said the doctor. “These materials could be impure or incorrectly dosed.”
Producer Position
A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this time no one can market [it] for personal consumption,” they explained, adding that any product “misleadingly claiming itself as a company experimental substance not yet authorized … may subject users to possibly serious health risks”.
